GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

The U.S. Centers for Disease Control and Prevention's vaccine experts are expected to vote on expanding access to respiratory ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to ...

“We are proud that ABRYSVO has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect ...